eClinical Technology and Industy News

Agenus Data at CTOS 2022 Highlight Durable Clinical Responses of Botensilimab / Balstilimab Combination in Advanced Sarcoma

  • Overall response rate (ORR) of 46% and disease control rate (DCR) of 69% in heavily pre-treated patients who have received a median of 3 prior lines of therapy
  • Patient responses include sarcoma subtypes that historically do not respond to immunotherapy, including responses in 3 of 4 patients with visceral angiosarcoma
  • 67% of patient responses have exceeded one year and remain ongoing at data cut-off
  • Phase 2 trial of botensilimab/balstilimab in sarcomas planned for 2023

Excerpt from the Press Release:

LEXINGTON, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) — Agenus (Nasdaq: AGEN), an immuno-oncology company with a broad pipeline targeting cancer and infectious disease, announced expanded data from the Company’s Phase 1 study of botensilimab (Fc-enhanced anti-CTLA-4) and balstilimab (anti-PD-1) in patients with advanced sarcoma. The data demonstrate that the combination offers strong durability and superior efficacy compared to what has been reported in separate trials for standard of care and other investigational therapies in sarcoma, including in sarcoma subtypes historically unresponsive to immunotherapy. The results will be presented tomorrow in an oral presentation at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting in Vancouver, BC, Canada.

“The superior efficacy and durable responses achieved with botensilimab and balstilimab in advanced sarcoma build on the unprecedented clinical responses we have observed with this combination in multiple cold, treatment-resistant cancers,” said Steven O’Day, MD, Chief Medical Officer at Agenus. “We are advancing multiple randomized Phase 2 trials to evaluate the therapeutic potential of this agent across a range of solid tumors.”

Study Design and Highlights:

A total of 13 evaluable patients with advanced sarcoma received either 1 or 2 mg/kg botensilimab every 6 weeks and 3 mg/kg balstilimab every 2 weeks.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary EDC Platforms

Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?